Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-04-18
1999-02-16
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 12, 514 21, 424 851, 424 852, A61K 3820
Patent
active
058720952
ABSTRACT:
Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
REFERENCES:
patent: 5011778 (1991-04-01), Newman et al.
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5162361 (1992-11-01), Rosenthal et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5359032 (1994-10-01), Dayer et al.
patent: 5455330 (1995-10-01), Haskill et al.
Ohlsson et al., "Interleukin-1 receptor antagonist reduces mortality from endotoxin shock," Nature, 348:550-552 (Dec. 6, 1990).
Koch et al., "Expression of Interleukin-1 and Interleukin-1 Receptor Antagonist by Human Rheumatoid Synovial Tissue Macrophages," Clinical Immunology and Immunopathology, 65(1):23-29 (Oct. 1992).
Duff, et al., "Tumor necrosis factor (TNF) and interleukin 1 (IL-1) in arthritis," Immunobiology, 75(1/2) Abst. No. 17, pp. 10-11 (1987).
Lebsack et al., "Subcutaneous IL-1 Receptor Antagonist In Patients With Rheumatoid Arthritis," Arth. Rheumat., 34: Abst. No. 73, S45 (1991).
Wall Street Journal, "Failed Drugs Are Revived For Arthritis," pp. B1 and B7 (Jul. 19, 1997).
Tilg et al., "Antiinflammatory Properties of Hepatic Acute Phase Proteins: Preferential Induction of Interleukin 1 (IL-1) Receptor Antagonist Over IL-1.beta. Synthesis by Human Peripheral Blood Mononuclear Cells," J. Exp. Med., 178:1629-1636 (Nov. 1993).
Dinarello et al., "Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro," Immunology Today, 12(11):404-410 (Nov. 11, 1991).
Whicher, "Control of Receptor Appetite," (Apr. 1990).
Simpson, et al., "Reduction of Experimental Canine Myocardial Reperfusion Injury by a Monoclonal Antibody (Anti-Mol, Anti-CD11 b) That Inhibits Leukocyte Adhesion," J., Clin. Invest., 81:624-629 (Feb. 1988).
Dorland's Illustrated Medical Dictionary, 24th Ed., W.B. Saunders Company, Philadelphia, PA., p. 760 (1965).
Vedder, et al., "A Monoclonal Antibody to the Adherence-promoting Leukocyte Glycoprotein, CD 18, Reduces Organ Injury and Improves Survival from Hemorrhagic Shock and Resuscitation in Rabbits," J. Clin. Invest., 81:939-944 (1988).
Cotran, et al., "Induction and Detection of a Human Endothelial Activation Antigen In Vivo," Brief Definitive Report, J. Exp. Med. 164:661-666, (Aug. 1986).
BNA's Patent, Trademark & Copyright Journal, 41:62-63 (Nov. 1990).
U.S. Patent and Trademark Office, 1053 OG 11-12, (Apr. 2, 1985).
Buchan, et al., "Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1.alpha.," Clin. Exp. Immunol. 73:449-455 (Mar. 1988).
Dinarello, et al., "Multiple Biological Activities of Human Recombinant Interleukin 1," J. Clin. Invest., 77:1734-1739 (Jun. 1986).
Gosset, et al., "Production of an Interleukin-1 Inhibitor Factor by Human Alveolar Macrophages from Normals and Allergic Asthmatic Patients," Am Rev. Respir. Dis., 138:40-46 (1988).
Oppenheim, et al., "There is More Than One Interleukin 1," Immunology Today, Reviews, 7:45-56 No. 2 (1986).
Seckinger, et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1.alpha. and 1.beta. But Not Tumor Necrosis Factor .alpha.," The Journal of Immunology, 139:1541-1545, No. 5 (Sep. 1, 1987).
Palaszynski, Biochem. Biophys Res. Comm 147, 1987, pp. 204-211.
Maliszewski et al J Immunol 144, 1990, pp. 3028-3033.
Cominelli et al, J Clin Invest, 86, 1990, pp. 972-980.
Fanslow et al, Science, 248; 1990, pp. 734-742.
Gershenwald et al PNAS 87, 1990, pp. 4966-4970.
Carter et al, Nature 344, 1990, pp. 633-638.
Esenberg et al, Nature 343, 1990, pp. 336-346.
Hannum et al, Nature 343 1990, pp. 336-346.
Haskill John Stephen
Ralph Peter
Blackburn Robert P.
Chiron Corporation
Draper Garnette D.
Pochopien Donald J.
Savereide Paul B.
LandOfFree
IL-1 receptor antagonists medicaments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-1 receptor antagonists medicaments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-1 receptor antagonists medicaments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062595